Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
34.17M | 38.91M | 26.00M | 110.78M | 85.08M | 16.60M | Gross Profit |
33.98M | 38.91M | 24.45M | 108.74M | 85.08M | 16.60M | EBIT |
-52.44M | -43.90M | -86.42M | 14.54M | -4.60M | -56.82M | EBITDA |
-40.08M | -77.14M | -235.06M | 39.84M | -5.16M | -65.59M | Net Income Common Stockholders |
-38.31M | -77.42M | -219.71M | 35.38M | -25.69M | -68.88M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
147.81M | 212.61M | 76.91M | 134.60M | 128.06M | 138.69M | Total Assets |
176.75M | 435.02M | 305.05M | 165.89M | 159.88M | 165.44M | Total Debt |
35.36M | 13.98M | 10.96M | 37.92M | 35.28M | 35.35M | Net Debt |
-90.05M | -198.63M | -65.96M | -68.51M | -78.78M | -103.34M | Total Liabilities |
196.32M | 441.82M | 745.23M | 72.06M | 137.36M | 183.44M | Stockholders Equity |
-19.57M | -6.80M | -440.18M | 93.83M | 22.52M | -18.01M |
Cash Flow | Free Cash Flow | ||||
-40.43M | -32.77M | -51.37M | -32.83M | -61.47M | 34.07M | Operating Cash Flow |
-30.86M | -23.67M | -51.16M | -31.63M | -60.38M | 34.88M | Investing Cash Flow |
-9.21M | -8.74M | 34.61M | -15.00M | -17.14M | -741.00K | Financing Cash Flow |
117.37M | 168.43M | -13.14M | 39.22M | 52.90M | 14.43M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
58 Neutral | $552.24M | ― | -34.26% | ― | 271.44% | 26.65% | |
56 Neutral | $346.87M | ― | -27.40% | ― | 15.40% | 35.42% | |
54 Neutral | $5.31B | 3.26 | -45.10% | 2.79% | 16.76% | 0.02% | |
51 Neutral | $478.84M | ― | -79.51% | ― | -100.00% | 10.73% | |
47 Neutral | $286.41M | ― | -938.38% | ― | 38.82% | -645.78% | |
43 Neutral | $403.03M | ― | -56.24% | ― | ― | 9.22% | |
41 Neutral | $471.00M | ― | -39.06% | ― | ― | -48.01% |
On April 29, 2025, Cartesian Therapeutics, Inc. announced that its Chief Technology Officer, Metin Kurtoglu, will end his employment with the company on May 1, 2025. Following this, he will transition to a consulting role from May 1, 2025, to April 30, 2026. The agreements include a separation deal where Dr. Kurtoglu will release any claims against the company in exchange for severance benefits, including 12 months’ salary, a pro-rated bonus, and accelerated vesting of equity awards.
On April 8, 2025, Cartesian Therapeutics announced 12-month efficacy and safety data from its Phase 2b trial of Descartes-08 for generalized myasthenia gravis (MG). The trial demonstrated sustained symptom improvement and a favorable safety profile, supporting outpatient administration. Notably, participants without prior biologic therapies showed the most compelling responses, with significant reductions in MG-ADL scores. The results reinforce Descartes-08’s potential to transform MG treatment, and the company plans to commence a Phase 3 trial in the second quarter of 2025.